Bengaluru, NFAPost: Novavax Inc. (Nasdaq: NVAX), a biotech company known for its next-gen vaccines for serious infectious diseases, today announced that Gregory M. Glenn (M.D and President of Research & Development) will present on the company’s COVID-19 vaccine ‘NVX-CoV2373′, at The New York Academy of Science (NYAS) event, ‘The Quest for a COVID-19 Vaccine.’
Webinar details are as follows:
| Presentation title: | Efficacy Data Updates from Novavax’ Protein-based Vaccine Candidate |
| Date: | February 2, 2021 |
| Time: | 4:00 pm ET |
| Presenter: | Dr. Glenn |
Novavax announced interim data last week on its protein-based COVID-19 vaccine candidate that demonstrated the efficacy of 89.3% in a pivotal Phase 3 clinical trial taking place in the United Kingdom (UK). The data from this UK Phase 3 trial and a South Africa Phase 2b study were the first to demonstrate clinical efficacy against newer circulating UK and South Africa COVID-19 variants.
To register for the webinar please visit the NYAS website. Presentation slides will be posted to the company’s website following the presentation here.
NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 was created using Novavax’ recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and is adjuvanted with Novavax’ patented saponin-based Matrix-M™ to enhance the immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 contains purified protein antigen and can neither replicate nor can it cause COVID-19.
In preclinical studies, NVX-CoV2373 induced antibodies that block the binding of spike protein to cellular receptors and provided protection from infection and disease. It was generally well-tolerated and elicited robust antibody response numerically superior to that seen in human convalescent sera in Phase 1/2 clinical testing.
NVX-CoV2373 is currently being evaluated in two pivotal Phase 3 trials: a trial in the U.K that completed enrollment in November and the PREVENT-19 trial in the U.S. and Mexico that began in December. It is also being tested in two ongoing Phase 2 studies that began in August: A Phase 2b trial in South Africa, and a Phase 1/2 continuation in the U.S. and Australia.
Matrix-M
Novavax’ patented saponin-based Matrix-M™ adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response.
For more information, visit www.novavax.com
